Selected research
Market Structure
Global Anti-Neprilysin Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Anti-Neprilysin Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Anti-Neprilysin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Anti-Neprilysin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Anti-Neprilysin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Anti-Neprilysin Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Anti-Neprilysin Antibody include Bioprojet SCR, Cipla Limited, Novartis International AG, Oceanic Pharmachem Pvt. Ltd, Pharmaleads SA and Theravance Biopharma Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Anti-Neprilysin Antibody market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Anti-Neprilysin Antibody and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Anti-Neprilysin Antibody revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Anti-Neprilysin Antibody market size, projected growth trends, production technologies, key applications, and end-use industries.
Anti-Neprilysin Antibody Segment by Company
Bioprojet SCR
Cipla Limited
Novartis International AG
Oceanic Pharmachem Pvt. Ltd
Pharmaleads SA
Theravance Biopharma Inc.
Anti-Neprilysin Antibody Segment by Type
Sacubitril
TD-0714
STR-324
PL-265
LHW-090
Anti-Neprilysin Antibody Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Anti-Neprilysin Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Neprilysin Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Anti-Neprilysin Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Neprilysin Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Anti-Neprilysin Antibody in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Anti-Neprilysin Antibody industry.
Chapter 3: Detailed analysis of Anti-Neprilysin Antibody companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-Neprilysin Antibodyrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Sacubitril
- TD-0714
- STR-324
- PL-265
- LHW-090
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Companies covered
- Bioprojet SCR
- Cipla Limited
- Novartis International AG
- Oceanic Pharmachem Pvt. Ltd
- Pharmaleads SA
- Theravance Biopharma Inc.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Anti-Neprilysin Antibody Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Sacubitril
- 1.2.3 TD-0714
- 1.2.4 STR-324
- 1.2.5 PL-265
- 1.2.6 LHW-090
- 1.3 Market Analysis by Application
- 1.3.1 Global Anti-Neprilysin Antibody Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Retail Pharmacies
- 1.3.3 Online Pharmacies
- 1.3.4 Hospital Pharmacies
- 1.4 Global Market Growth Prospects
- 1.5 Global Anti-Neprilysin Antibody Growth Trends by Region
- 1.5.1 Global Anti-Neprilysin Antibody Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Anti-Neprilysin Antibody Market Size by Region (2021-2026)
- 1.5.3 Anti-Neprilysin Antibody Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Anti-Neprilysin Antibody Market Dynamics
- 2.1 Anti-Neprilysin Antibody Industry Trends
- 2.2 Anti-Neprilysin Antibody Industry Drivers
- 2.3 Anti-Neprilysin Antibody Industry Opportunities and Challenges
- 2.4 Anti-Neprilysin Antibody Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Anti-Neprilysin Antibody Revenue by Company (2021-2026)
- 3.2 Global Anti-Neprilysin Antibody Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Anti-Neprilysin Antibody Key Company Head office and Area Served
- 3.4 Global Anti-Neprilysin Antibody Company, Product Type & Application
- 3.5 Global Anti-Neprilysin Antibody Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Anti-Neprilysin Antibody Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Anti-Neprilysin Antibody Players Market Share by Revenue in 2025
- 3.6.3 2025 Anti-Neprilysin Antibody Tier 1, Tier 2, and Tier 3
4 Anti-Neprilysin Antibody Market by Type
- 4.1 Global Anti-Neprilysin Antibody Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Anti-Neprilysin Antibody Market Size by Type (2021-2032)
- 4.3 Global Anti-Neprilysin Antibody Market Size Share by Type (2021-2032)
5 Anti-Neprilysin Antibody Market by Application
- 5.1 Global Anti-Neprilysin Antibody Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Anti-Neprilysin Antibody Market Size by Application (2021-2032)
- 5.3 Global Anti-Neprilysin Antibody Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Bioprojet SCR
- 6.1.1 Bioprojet SCR Company Information
- 6.1.2 Bioprojet SCR Business Overview
- 6.1.3 Bioprojet SCR Anti-Neprilysin Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Bioprojet SCR Anti-Neprilysin Antibody Product Portfolio
- 6.1.5 Bioprojet SCR Recent Developments
- 6.2 Cipla Limited
- 6.2.1 Cipla Limited Company Information
- 6.2.2 Cipla Limited Business Overview
- 6.2.3 Cipla Limited Anti-Neprilysin Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Cipla Limited Anti-Neprilysin Antibody Product Portfolio
- 6.2.5 Cipla Limited Recent Developments
- 6.3 Novartis International AG
- 6.3.1 Novartis International AG Company Information
- 6.3.2 Novartis International AG Business Overview
- 6.3.3 Novartis International AG Anti-Neprilysin Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Novartis International AG Anti-Neprilysin Antibody Product Portfolio
- 6.3.5 Novartis International AG Recent Developments
- 6.4 Oceanic Pharmachem Pvt. Ltd
- 6.4.1 Oceanic Pharmachem Pvt. Ltd Company Information
- 6.4.2 Oceanic Pharmachem Pvt. Ltd Business Overview
- 6.4.3 Oceanic Pharmachem Pvt. Ltd Anti-Neprilysin Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Oceanic Pharmachem Pvt. Ltd Anti-Neprilysin Antibody Product Portfolio
- 6.4.5 Oceanic Pharmachem Pvt. Ltd Recent Developments
- 6.5 Pharmaleads SA
- 6.5.1 Pharmaleads SA Company Information
- 6.5.2 Pharmaleads SA Business Overview
- 6.5.3 Pharmaleads SA Anti-Neprilysin Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Pharmaleads SA Anti-Neprilysin Antibody Product Portfolio
- 6.5.5 Pharmaleads SA Recent Developments
- 6.6 Theravance Biopharma Inc.
- 6.6.1 Theravance Biopharma Inc. Company Information
- 6.6.2 Theravance Biopharma Inc. Business Overview
- 6.6.3 Theravance Biopharma Inc. Anti-Neprilysin Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Theravance Biopharma Inc. Anti-Neprilysin Antibody Product Portfolio
- 6.6.5 Theravance Biopharma Inc. Recent Developments
7 North America
- 7.1 North America Anti-Neprilysin Antibody Market Size (2021-2032)
- 7.2 North America Anti-Neprilysin Antibody Market Size by Type
- 7.2.1 North America Anti-Neprilysin Antibody Market Size by Type (2021-2026)
- 7.2.2 North America Anti-Neprilysin Antibody Market Size by Type (2027-2032)
- 7.2.3 North America Anti-Neprilysin Antibody Market Share by Type (2021-2032)
- 7.3 North America Anti-Neprilysin Antibody Market Size by Application
- 7.3.1 North America Anti-Neprilysin Antibody Market Size by Application (2021-2026)
- 7.3.2 North America Anti-Neprilysin Antibody Market Size by Application (2027-2032)
- 7.3.3 North America Anti-Neprilysin Antibody Market Share by Application (2021-2032)
- 7.4 North America Anti-Neprilysin Antibody Market Size by Country
- 7.4.1 North America Anti-Neprilysin Antibody Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Anti-Neprilysin Antibody Market Size by Country (2021-2026)
- 7.4.3 North America Anti-Neprilysin Antibody Market Size by Country (2027-2032)
- 7.4.4 North America Anti-Neprilysin Antibody Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Anti-Neprilysin Antibody Market Size (2021-2032)
- 8.2 Europe Anti-Neprilysin Antibody Market Size by Type
- 8.2.1 Europe Anti-Neprilysin Antibody Market Size by Type (2021-2026)
- 8.2.2 Europe Anti-Neprilysin Antibody Market Size by Type (2027-2032)
- 8.2.3 Europe Anti-Neprilysin Antibody Market Share by Type (2021-2032)
- 8.3 Europe Anti-Neprilysin Antibody Market Size by Application
- 8.3.1 Europe Anti-Neprilysin Antibody Market Size by Application (2021-2026)
- 8.3.2 Europe Anti-Neprilysin Antibody Market Size by Application (2027-2032)
- 8.3.3 Europe Anti-Neprilysin Antibody Market Share by Application (2021-2032)
- 8.4 Europe Anti-Neprilysin Antibody Market Size by Country
- 8.4.1 Europe Anti-Neprilysin Antibody Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Anti-Neprilysin Antibody Market Size by Country (2021-2026)
- 8.4.3 Europe Anti-Neprilysin Antibody Market Size by Country (2027-2032)
- 8.4.4 Europe Anti-Neprilysin Antibody Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Anti-Neprilysin Antibody Market Size (2021-2032)
- 9.2 China Anti-Neprilysin Antibody Market Size by Type
- 9.2.1 China Anti-Neprilysin Antibody Market Size by Type (2021-2026)
- 9.2.2 China Anti-Neprilysin Antibody Market Size by Type (2027-2032)
- 9.2.3 China Anti-Neprilysin Antibody Market Share by Type (2021-2032)
- 9.3 China Anti-Neprilysin Antibody Market Size by Application
- 9.3.1 China Anti-Neprilysin Antibody Market Size by Application (2021-2026)
- 9.3.2 China Anti-Neprilysin Antibody Market Size by Application (2027-2032)
- 9.3.3 China Anti-Neprilysin Antibody Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Anti-Neprilysin Antibody Market Size (2021-2032)
- 10.2 Asia Anti-Neprilysin Antibody Market Size by Type
- 10.2.1 Asia Anti-Neprilysin Antibody Market Size by Type (2021-2026)
- 10.2.2 Asia Anti-Neprilysin Antibody Market Size by Type (2027-2032)
- 10.2.3 Asia Anti-Neprilysin Antibody Market Share by Type (2021-2032)
- 10.3 Asia Anti-Neprilysin Antibody Market Size by Application
- 10.3.1 Asia Anti-Neprilysin Antibody Market Size by Application (2021-2026)
- 10.3.2 Asia Anti-Neprilysin Antibody Market Size by Application (2027-2032)
- 10.3.3 Asia Anti-Neprilysin Antibody Market Share by Application (2021-2032)
- 10.4 Asia Anti-Neprilysin Antibody Market Size by Country
- 10.4.1 Asia Anti-Neprilysin Antibody Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Anti-Neprilysin Antibody Market Size by Country (2021-2026)
- 10.4.3 Asia Anti-Neprilysin Antibody Market Size by Country (2027-2032)
- 10.4.4 Asia Anti-Neprilysin Antibody Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Anti-Neprilysin Antibody Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Anti-Neprilysin Antibody Market Size by Type
- 11.2.1 South America, Middle East & Africa Anti-Neprilysin Antibody Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Anti-Neprilysin Antibody Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Anti-Neprilysin Antibody Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Anti-Neprilysin Antibody Market Size by Application
- 11.3.1 South America, Middle East & Africa Anti-Neprilysin Antibody Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Anti-Neprilysin Antibody Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Anti-Neprilysin Antibody Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Anti-Neprilysin Antibody Market Size by Country
- 11.4.1 South America, Middle East & Africa Anti-Neprilysin Antibody Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Anti-Neprilysin Antibody Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Anti-Neprilysin Antibody Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Anti-Neprilysin Antibody Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst